INCY – incyte corporation (US:NASDAQ)

DELAYED

^$ usd


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

1D

5D

1M

3M

YTD

1Y

3Y

1 Day INCY SPY QQQ SPX

Date

Time

Symbol

Headline

Impact

Incyte (INCY) had its price target lowered by UBS Group AG from $104.00 to $94.00. They now have a "neutral" rating on the stock.

Incyte Announces Executive Leadership Appointments

Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.

Incyte (INCY) had its "overweight" rating reaffirmed by Barclays PLC.

Incyte: An Undervalued Healthcare Gem [Seeking Alpha]

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Incyte (INCY) was downgraded by Weiss Ratings from "buy (b-)" to "hold (c+)".

Low

Incyte at Barclays: Maps Post-Jakafi Growth With New Launches and Phase III Pipeline Push [Yahoo! Finance]

Date

Time

Symbol

Company Name

Action

%Chg

incyte corporation

incyte corporation

incyte corporation

incyte corporation

Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.

Date

Time

Action

From

To

Firm

Impact

%Chg

details

Date

Time

Symbol

Headline

Impact

Form SCHEDULE 13G/A INCYTE CORP Filed by: VANGUARD GROUP INC

Form 4 INCYTE CORP For: Mar 25 Filed by: Trotta Matteo

Form 8-K INCYTE CORP For: Mar 25

Form 4 INCYTE CORP For: Mar 17 Filed by: CAGNONI PABLO J

Form 144 INCYTE CORP Filed by: CAGNONI PABLO J

Form 8-K INCYTE CORP For: Feb 27

Form 4 INCYTE CORP For: Feb 19 Filed by: CAGNONI PABLO J

Form 144 INCYTE CORP Filed by: CAGNONI PABLO J

Stock Stats

News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings

Order Stats
Sub-Penny

Odd Lot

Avg. bid-ask spread

Avg. bid / ask size

Shares at ask / bid

Off exchange

Top News Gainers

4/5 Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium 7.1%

7/30 Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs 6.4%

3/13 Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. They now have a $83.00 price target on the stock. 6.4%

3/26 Incyte Names New Member to Its Board of Directors 5.9%

1/13 Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.7%

11/25 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting 5.3%

4/15 Form 4 INCYTE CORP For: Apr 13 Filed by: Pasquale Maria E 5.2%

2/18 Form 4 INCYTE CORP For: Feb 13 Filed by: Pasquale Maria E 4.0%

9/19 Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J 4.0%

3/24 Blair likes Incyte in premarket analyst action [Seeking Alpha] 3.5%

Top News Decliners

1/2 Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease -9.4%

5/10 Form 4 INCYTE CORP For: May 09 Filed by: Iyengar Vijay K -6.1%

3/26 Form 8-K INCYTE CORP For: Mar 25 -5.6%

6/7 Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP -5.0%

9/23 Incyte to Host Investor Conference Call from ESMO 2019 -4.6%

1/28 Incyte's skin disease drug meets main goal in late-stage study [Reuters] -3.8%

3/10 Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating [Investor's Business Daily] -3.2%

9/27 Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma -3.2%

9/12 Incyte Co. (NASDAQ: INCY) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating on the stock. -3.1%

8/27 BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 -3.1%

Don’t Miss Out On The Next BIG Stock Move

INCY – incyte corporation (US:NASDAQ)

DELAYED

^$ usd

1D

5D

1M

3M

YTD

1Y

3Y


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

INCY

SPY

QQQ

SPX

INCY – incyte corporation (US:NASDAQ)

DELAYED

^$ usd

1D

5D

1M

3M

YTD

1Y

3Y


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

INCY SPY QQQ SPX

Stock Stats

News Stats
Order Stats


All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings


Sub-Penny

Odd Lot

Avg. bid-ask spread

Avg. bid / ask size

Shares at ask / bid

Off exchange

Stock Stats

Order Stats


Sub-Penny

Odd Lot

Avg. bid-ask spread

Avg. bid / ask size

Shares at ask / bid

Off exchange

News Stats


All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings

News

Incyte (INCY) had its price target lowered by UBS Group AG from $104.00 to $94.00. They now have a "neutral" rating on the stock.

Incyte Announces Executive Leadership Appointments

Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.

Incyte (INCY) had its "overweight" rating reaffirmed by Barclays PLC.

Incyte: An Undervalued Healthcare Gem [Seeking Alpha]

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Incyte (INCY) was downgraded by Weiss Ratings from "buy (b-)" to "hold (c+)".

Incyte at Barclays: Maps Post-Jakafi Growth With New Launches and Phase III Pipeline Push [Yahoo! Finance]

Tracking Baker Brothers Portfolio - Q4 2025 Update [Seeking Alpha]

-5.4%

BEAT

-5.7%

BEAT

-0.7%

BEAT

-1.7%

MISS

Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.

Evercore ISI Group

Form SCHEDULE 13G/A INCYTE CORP Filed by: VANGUARD GROUP INC

Form 4 INCYTE CORP For: Mar 25 Filed by: Trotta Matteo

Form 8-K INCYTE CORP For: Mar 25

Form 4 INCYTE CORP For: Mar 17 Filed by: CAGNONI PABLO J

Form 144 INCYTE CORP Filed by: CAGNONI PABLO J

Form 8-K INCYTE CORP For: Feb 27

Form 4 INCYTE CORP For: Feb 19 Filed by: CAGNONI PABLO J

Form 144 INCYTE CORP Filed by: CAGNONI PABLO J

Form SCHEDULE 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP

Show more

Top News Gainers

4/5 Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium 7.1%

7/30 Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs 6.4%

3/13 Incyte Co. (NASDAQ: INCY) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. They now have a $83.00 price target on the stock. 6.4%

3/26 Incyte Names New Member to Its Board of Directors 5.9%

1/13 Incyte Co. (NASDAQ: INCY) had its "buy" rating re-affirmed by analysts at Cowen Inc. 5.7%

11/25 Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting 5.3%

4/15 Form 4 INCYTE CORP For: Apr 13 Filed by: Pasquale Maria E 5.2%

2/18 Form 4 INCYTE CORP For: Feb 13 Filed by: Pasquale Maria E 4.0%

9/19 Form 4 INCYTE CORP For: Sep 18 Filed by: SWAIN PAULA J 4.0%

3/24 Blair likes Incyte in premarket analyst action [Seeking Alpha] 3.5%

Top News Decliners

1/2 Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease -9.4%

5/10 Form 4 INCYTE CORP For: May 09 Filed by: Iyengar Vijay K -6.1%

3/26 Form 8-K INCYTE CORP For: Mar 25 -5.6%

6/7 Form SC 13D/A INCYTE CORP Filed by: BAKER BROS. ADVISORS LP -5.0%

9/23 Incyte to Host Investor Conference Call from ESMO 2019 -4.6%

1/28 Incyte's skin disease drug meets main goal in late-stage study [Reuters] -3.8%

3/10 Incyte Joins Elite List Of Stocks With 95-Plus Composite Rating [Investor's Business Daily] -3.2%

9/27 Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma -3.2%

9/12 Incyte Co. (NASDAQ: INCY) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating on the stock. -3.1%

8/27 BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019 -3.1%